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Charged multivesicular body protein 1A/Chromatin modifying protein 1A (CHMP1A) is a
member of the ESCRT-III (endosomal sorting complex required for transport-III)
complex1–2, but is also suggested to localize to the nuclear matrix and regulate chromatin
structure3. Here we show that loss-of-function mutations to human CHMP1A cause reduced
cerebellar size (pontocerebellar hypoplasia) and reduced cerebral cortical size
(microcephaly). CHMP1A mutant cells show impaired proliferation, with increased
expression of INK4A, a negative regulator of stem cell proliferation, and chromatin
immunoprecipitation suggests a loss of the normal INK4A repression by BMI in these cells.
Morpholino-based knockdown of zebrafish chmp1a resulted in brain defects resembling
those seen after bmi1a and bmi1b knockdown, which were partially rescued by INK4A
orthologue knockdown, further supporting links between CHMP1A and BMI1-mediated
regulation of INK4A. Our results suggest that CHMP1A serves as a critical link between
cytoplasmic signals and BMI1-mediated chromatin modifications that regulate proliferation
of CNS progenitor cells.
As part of ongoing studies of human disorders of neural progenitor proliferation, we
identified three families characterized by underdevelopment of the cerebellum, pons, and
cerebral cortex (Fig. 1a–d). In a consanguineous pedigree of Peruvian origin, three children
in two branches were affected (Fig. 1e; Family 1). Two additional pedigrees from Puerto
Rico showed similar pontocerebellar hypoplasia and microcephaly (Fig. 1e; Family 2 and 3).
Brain MRI of affected individuals from all families show severe reduction of the cerebellar
vermis and hemispheres. Strikingly, the cerebellar folds (“folia”) are relatively preserved
despite the extremely small cerebellar size (Fig. 1a–d, Supplementary Videos 1, 2). All
affected individuals had severe pontocerebellar hypoplasia, though affected individuals in
Family 1 showed better motor and cognitive function than those in Family 2 and 3
(Supplementary Note, Clinical Information).
Genome-wide linkage analysis of Family 1 and 2 using single nucleotide polymorphism
(SNP) microarrays implicated only one region on chromosome 16q as linked and
homozygous in all six affected individuals (Fig. 1e, Supplementary Fig. 1), with a maximum
multipoint LOD score of 3.68 (Fig. 1e). Although Families 2 and 3 are not highly
informative for linkage analysis, their shared homozygosity provides additional support for
this locus. Furthermore, Families 2 and 3 shared the same haplotype (Supplementary Fig. 1),
suggesting a founder effect. Sequencing of 42 genes within the candidate interval on
16q24.3 revealed homozygous variants predicted to be deleterious in the CHMP1A gene
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tonly. CHMP1A consists of seven exons encoding a 196 amino acid protein (Supplementary
Note, CHMP1A isoforms). Affected individuals in Family 2 and 3 had a homozygous
nonsense variant in exon 3, predicted to prematurely terminate translation (c.88C>T; Q30X;
Fig. 2a). Family 1 showed a homozygous variant in intron 2 of CHMP1A (c.28-13G>A; Fig.
2a) predicted to create an aberrant splice acceptor site leading to an 11 base pair insertion
into the spliced mRNA product (Supplementary Fig. 2a). The two mutations were absent
from dbSNP, 281 neurologically normal European control DNA samples (562
chromosomes), the 1000 Genomes Project database4, and approximately 5000 control
exomes from the NHLBI Exome Sequencing Project. We sequenced CHMP1A in 64
individuals with other cerebellar anomalies without finding additional mutations, but none
of these patients shared the rare and distinctive pattern of hypoplasia seen in the individuals
with CHMP1A mutations.
RT-PCR analysis of CHMP1A in lymphoblastoid cells from affected individuals from
Family 1 (CH3101 and CH3105) identified the predicted aberrant transcript with the 11 base
pair insertion and a second aberrant transcript with a 21 base pair insertion, but no normal
CHMP1A transcript (Supplementary Fig. 2b). In the parents of affected children from
Family 1, and in unaffected control samples, only the normal transcript was detected,
suggesting that the abnormal splice products are unstable. Western blot analysis revealed a
single 24 kilodalton band in a normal control individual, but no corresponding band was
detected in affected individuals from Families 1 or 2 (CH3101 and CH2401, respectively;
Fig. 2c). Normalized to the loading control, levels of CHMP1A were 50% in the parent
(CH3104). Hence this genetic study establishes CHMP1A null mutations as the cause of
pontocerebellar hypoplasia and microcephaly in these pedigrees.
CHMP1A has been assigned two distinct putative functions, as both a chromatin modifying
protein, and a charged multivesicular body protein1,3. CHMP1A was originally identified as
a binding partner of the Polycomb group protein Pcl (Polycomblike)3. In the nucleus, it has
been suggested to recruit the Polycomb group transcriptional repressor BMI1 to
heterochromatin, and overexpressed CHMP1A has been shown to arrest cells in S-phase 3.
In the cytoplasm, CHMP1A is part of the ESCRT-III complex (endosomal sorting complex
required for transport)1–2. ESCRT-III complex localizes to endosomes and interacts with
VPS4A and VPS4B5 to assist in the trafficking of ubiquitinated cargo proteins to the
lysosome for degradation6.
We investigated potential relationships of CHMP1A to Polycomb function by analysis of
cell lines from two patients harboring different CHMP1A mutations (CH3101 from Family
1, and CH2401 from Family 2), which show severely impaired doubling times compared to
control cell lines, suggesting essential roles of CHMP1A in regulating cell proliferation (Fig.
2d). In order to examine BMI1 function in these cells, we performed quantitative PCR
analysis of expression of the BMI1 target locus CDKN2A, which encodes alternative
transcripts INK4A (also known as p16INK4a) and ARF (also known as p14ARF) in human.
This revealed abnormally increased expression of INK4A, the isoform implicated in
cerebellar development, but not of ARF (Fig. 2e), suggesting de-repression of INK4A.
Chromatin immunoprecipitation with a BMI1 antibody in control cell lines showed an
approximately eight-fold enrichment of BMI1 binding at INK4A promoter DNA, relative to
a control region 7kb upstream, whereas cells from an affected individual (CH2401) showed
only about half this effect (Fig. 2f). Enrichment of BMI1 at the ARF promoter was not
substantial in this assay, and was similar in both control and cell lines from affected
individuals, consistent with the specificity of regulation of the INK4A isoform by BMI1
(Fig. 2f). Bmi1 suppresses the Cdkn2a locus via Polycomb-mediated H2A
monoubiquitination, and is required for neural stem cell self-renewal7. Our evidence
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tsuggests a role for CHMP1A in mediating BMI1-directed epigenetic silencing at the INK4A
promoter, but not at the ARF promoter.
We further explored the relationship between CHMP1A and BMI1 using morpholino-based
knockdown experiments in zebrafish. Knockdown of the zebrafish CHMP1A orthologue
(chmp1a) resulted in reduced cerebellum and forebrain volume, similar to the effects of
human CHMP1A mutations and zebrafish knockdown of BMI1 orthologues (Fig. 3a–e,
Supplementary Fig. 3, 4). A second morpholino led to a similar phenotype, and both
morpholinos were partially rescued by human CHMP1A mRNA, confirming the specificity
(Supplementary Fig. 4). The cerebellum consists of 5 major cells types, with the principal
cell, known as the Purkinje cell, deriving from the ventricular epithelium, whereas granule
cells derive from a separate progenitor pool known as the rhombic lip. Granule cell
precursors then migrate over the outer surface of the cerebellum and form the external
germinal layer (EGL) before migrating radially past the Purkinje cells to settle in the internal
granule layer (IGL)8. Within the chmp1a morphant cerebellum, the internal granule and
molecular layers were severely affected (Fig. 3a, b), which is consistent with the relatively
preserved folia pattern of the human cerebellum (thought to be primarily established by
Purkinje cells) and severely reduced volume (determined mainly by granule cell quantity).
We then tested genetic interactions between chmp1a and the zebrafish orthologue of INK4A
(cdkn2a). Knockdown of cdkn2a alone did not result in noticeable abnormalities, and double
knockdown of chmp1a and cdkn2a resulted in partial rescue of the brain morphology defects
seen with chmp1a knockdown (Fig. 3f, g). This was analogous to the rescue of the Bmi1
knockout mouse cerebellar phenotype seen in the Bmi1 and Cdkn2a double knockout mice9.
Of note, there are also parallels in brain morphology between individuals with CHMP1A
mutations and Bmi1-deficient mice, which show cerebellar hypoplasia10–11 (Fig. 3h, i). In
Bmi1-null mice, the cerebellar architecture was generally preserved, but the thickness of the
granular and molecular layers was markedly reduced10, and Bmi1-deficient mice show a
modest reduction in cerebral volume10,12, similar to individuals with CHMP1A mutations
(Supplementary Note, Clinical Information).
Subcellular localization of Chmp1a appears to vary depending on the cell type. Confocal
images of NIH 3T3 cells show prominent exclusion of Chmp1a from the nucleus, where
Bmi1 is seen (Fig. 4a). On the other hand, confocal images of HEK293T cells, while still
showing predominantly cytoplasmic localization, show some nuclear immunoreactivity as
well (Fig. 4b). Primary cultures of cerebellar granule cells also show predominant
cytoplasmic localization, along with a speckled nuclear pattern (Fig. 4c). Overexpression of
HA-tagged Chmp1a in cultured granule cells shows abundant nuclear Chmp1a with a
punctate expression pattern, confirming the speckled nuclear localization of native Chmp1a
(Fig. 4d), and consistent with earlier reports that Chmp1a can appear in the nucleus3.
However, even with overexpression, Chmp1a and Bmi1 do not prominently co-localize
within the nucleus, also in agreement with previous data3.
Immunohistochemical studies of mouse developing cerebellum and cerebral cortex revealed
widespread expression of Chmp1a in dividing and postmitotic cells. Chmp1a
immunoreactivity is seen in the nucleus and cytoplasm of EGL, Purkinje and IGL cells (Fig.
4e, f, Supplementary Fig. 5). In the nucleus of these cells, Chmp1a immunoreactivity is seen
in a speckled pattern. These speckles may be seen adjacent to Bmi1 signals, but they usually
do not colocalize (Fig. 4f, Supplementary Fig. 5). At later stages of cerebellar development
(P4, P10 and P29), Chmp1a expression persists in Purkinje and granule cells
(Supplementary Fig. 6). E13.5 cerebral cortex shows widespread Chmp1a expression in the
neuroepithelial cells (Fig. 4g). In the postnatal cerebral cortex (P4, P10 and P29), Chmp1a
expression in postmitotic neurons of the cortical plate gradually decreases, and becomes
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talmost undetectable by P29 (Supplementary Fig. 6). These expression studies confirm that
Bmi1 and Chmp1a are often expressed in the same cells. On the other hand, the absence of
widespread subcellular co-localization of Bmi1 and Chmp1a suggests that the regulation of
Bmi1 by Chmp1a is perhaps not mediated by direct physical interaction.
Our data implicate CHMP1A as an essential CNS regulator of BMI1, which in turn is a key
regulator of stem cell self-renewal. Chmp1a’s dual cytoplasmic and nuclear localization, and
its connection to the ESCRT-III complex, position Chmp1a as a potentially crucial link
between cytoplasmic signals and the global regulation of stem cells via the Polycomb
complex.
Online Methods
Genetic screening
The genetic study was approved by the Institutional Review Boards of Boston Children’s
Hospital and University of Chicago. Appropriate informed consent was obtained from all
involved human subjects.
The affected individuals and their parents from Family 1 and the affected individuals from
Family 2 were subjected to genome-wide SNP screen with Affymetrix GeneChip Human
Mapping 250K Sty Array, performed at the Microarray Core of the Dana Farber Cancer
Institute. Microsatellite markers for fine mapping were identified using the UCSC Human
Genome Browser13 and were synthesized with fluorescent-labels (Sigma-Genosys). Two
point and multipoint LOD scores were calculated using Allegro14, assuming recessive
inheritance with full penetrance and a disease allele frequency of 0.001. Sequencing primers
were designed using Primer315, and genomic DNA was sequenced using standard Sanger
technology. Control DNA samples from neurologically normal individuals of European
descent were obtained from the Coriell Cell Repositories (Coriell Institute for Medical
Research). All nucleotide numbers are in reference to CHMP1A isoform 2 cDNA
(NM_002768, in which A of the ATG start site is +1) from the UCSC Genome Browser.
Analysis of CHMP1A splicing
Splice prediction software NetGene216 was used to determine the effect of the Family 1
allele on CHMP1A splicing. EBV-transformed lymphocytes were grown in RPMI-1640
with 15% (v/v) fetal bovine serum and 1% (v/v) penicillin/streptomycin in a humidified
incubator at 37°C in 5% CO2. RNA was isolated using the RNeasy Mini Kit (Qiagen). Total
RNA (5μg) was used for first-strand synthesis with oligo(dT) primers and the SuperScript
III First-Strand Synthesis SuperMix (Invitrogen), and 1μl of the product was used for the
subsequent PCR reaction, with primers from 5′ UTR to exon 6 of CHMP1A (NM_002768).
Primer sequences are listed in Supplementary Table 1.
Proliferation assay of lymphoblastoid cell lines
EBV-transformed lymphoblastoid cell lines from eight control subjects and two affected
individuals (CH2401 and CH3101) were grown as described above. From each cell line, 20
million cells were grown, and then one million cells were aliquoted into four sets of five T25
flasks filled with 10ml of media. Each set was allowed to grow for 24, 48, 72, and 96 hours,
respectively. Cell densities were estimated using a hemocytometer.
Quantitative PCR
EBV-transformed lymphoblastoid cell lines were grown and cDNA was generated as
described above. INK4A and ARF levels were quantified using the StepOnePlus Real-Time
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tPCR System (Applied Biosystems), with GAPDH as a control. Primer sequences are listed
in Supplementary Table 1.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed as previously described17 with some
modifications. For a single experiment, 20 million EBV-transformed lymphoblastoid cells
and 4μg of the BMI1 antibody (Abcam, ab14389) were used. Quantitative PCR reactions
were performed using SYBR Green reagents (Applied Biosystems) and StepOnePlus real-
time PCR systems (Applied Biosystems). Primers were assessed for specificity by their melt
curves, and a standard curve was determined using four ten-fold serial dilutions for each
primer using the input DNA samples. Fold-enrichments for each ChIP sample were
normalized to input Ct. Primer sequences are listed in Supplementary Table 1.
Zebrafish morpholino experiments
ATG-targeting morpholinos were designed against chmp1a (chmp1a MO #1), bmi1a,
bmi1b, and the INK4A zebrafish orthologue (cdkn2a) (Gene Tools). In all experiments
where bmi1 morpholinos were used, bmi1a and bmi1b were injected together. Injections
were performed at the one-cell stage. Optimal doses for the chmp1a MO #1, bmi1a+b and
ink4a morpholinos were 4.5ng, 1.2ng, and 4.0ng, respectively. At 28 hours post-fertilization
(hpf), the embryos were visualized using a stereo microscope (Zeiss). In order to confirm the
specificity of the effects of the chmp1a MO #1 morpholino, a second ATG-targeting
chmp1a morpholino (chmp1a MO #2) was designed. For this experiment, the dosage of
chmp1a MO #1 and MO #2 injected was 6.0ng and 3.0ng, respectively. Morpholino
sequences are listed in Supplementary Table 1.
For the rescue experiment, morphants were screened at 28hpf and scored for the presence of
a defect in the angle of the head to the tail (measured at the otic vesicle) or a deviation in the
straightness of the tail18. Human CHMP1A cDNA was PCR amplified from control human
lymphoblastoid cell total RNA. Primer sequences are listed in Supplementary Table 1. The
PCR product was subcloned into the pCS2+ vector, and 5′ capped mRNA was synthesized
in vitro using the mMESSAGE kit (Ambion). mRNA was diluted in 0.1M KCl, and titrated
for the rescue experiments.
For the histological preparation, morphants were grown at 28°C for 5 days, fixed overnight
at 4°C in paraformaldehyde (PFA), then embedded in 3% low-melt agarose blocks (in
phosphate buffered saline), which were fixed again in 4% PFA/PBS overnight. The fixed
agarose blocks were embedded in paraffin and sectioned at 5μm thickness in the sagittal
plane. Sections were stained by standard techniques with hematoxylin and eosin, and
visualized using a brightfield microscope (Nikon).
For western blotting, zebrafish embryos were harvested at 48 hpf. They were dechorionated
and deyolked as described19, and treated with lysis buffer (10% SDS, 0.5M EDTA, 1X PBS)
containing cOmplete Mini Protease Inhibitor Cocktail (Roche). Lysates were mixed with 2X
Laemmli Sample Buffer, loaded onto NuPage 4–12% Bis-Tris gel (Invitrogen) and run at
100V for 2 hours. The gel was wet-transferred onto Immobilon-P transfer membrane
(Millipore) at 300mA for 1.5 hours at 4 C. The membrane was blocked with Odyssey
Blocking Buffer (LI-COR), and incubated with antibodies against Chmp1a (1:100; Abcam,
ab104103) and beta-actin (1:10000; Abcam, ab6275), and then with IRDye secondary
antibodies (LI-COR, 926–32212 and 926–68023). LI-COR Imaging System was used for
imaging and quantification.
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tImmunocytochemistry and immunohistochemistry
NIH 3T3 and HEK293T cells were grown in DMEM with 10% (v/v) fetal bovine serum and
1% (v/v) penicillin/streptomycin, fixed and stained with antibodies against Chmp1a (1:200;
Abcam, ab36679) and Bmi1 (1:250; Abcam, ab14389) using standard techniques, and
visualized on a confocal microscope (Nikon).
All animal work was approved by Harvard Medical School, Beth Israel Deaconess Medical
School and Boston Children’s Hospital Institutional Animal Care and Use Committees.
Cerebellar granule neuron cultures from euthanized, postnatal day 5 mouse pups were
prepared as described20. After dissociation, cell density was measured using a
hemocytometer and one million cells were plated on each poly-L-ornithine-coated coverslip
with 500μL plating media in a 24-well plate. After one day in vitro (DIV) in a 37 C
incubator, 20μL of 250μM AraC (cytosine-1-β-D-arabinofuranoside) was added to each
well to arrest mitosis of non-neurons. At 2 DIV, the conditioned media was collected from
each well, and the wells were washed with DMEM. The cells were then transfected with the
HA-Chmp1a mammalian expression construct (GeneCopoeia, EX-Mm15805-M06).
Transfection solution (87.6uL HBSS, 4.4μL of 2.5M calcium chloride, with 1.5μg of
plasmid DNA) was prepared at room temperature, and 35μL of the transfection solution was
added to a total of 400μL of conditioned media to each well. After 36 additional hours (4
DIV), cells were fixed with 4% PFA for 20 minutes at room temperature, washed with PBS,
and stained with antibodies against HA (1:100; Abcam, ab9110) and Bmi1 (1:250; Abcam,
ab14389). Untransfected cells were processed similarly and stained with antibodies against
Chmp1a (1:200; Abcam, ab36679) and Bmi1.
Tissues were perfused with 4% PFA, dissected and fixed overnight in 4% PFA, then
embedded in paraffin and sectioned at 5 or 8μm. After rehydration of the slides in serial
washes with xylene, 50% xylene/ethanol, 100%/70%/50%/30% ethanol, and finally PBS,
the slides were boiled in antigen retrieval solution (Retrievagen A; BD Biosciences) for 8
minutes in the autoclave. Slides were blocked with PBS with 0.1% Triton-X100
supplemented with 1% donkey serum for 1 hour at room temperature, followed by addition
of antibodies against Bmi1 (1:400; Millipore, clone F6), Chmp1a (1:300; Abcam, ab36679
and ab104103) or calbindin (Swant, CB300) in the blocking solution for overnight
incubation at 4 C. Slides were washed 3×5 minutes in PBS, and then developed with
secondary antibodies conjugated to Alexa-Fluor dyes (Invitrogen) for 1.5 hours at room
temperature. Slides were again washed 3×5 minutes in PBS, then mounted with
Fluoromount-G (SouthernBiotech) containing DAPI (1:1000), and visualized on a confocal
microscope (Nikon) or fluorescence microscope (Zeiss). For E13.5 and P2 cerebral cortex,
frozen section specimens were used. For frozen sections, heads of E13.5 mouse embryos
were directly fixed in 4% PFA, and P2 pups were perfused with 2ml 1X PBS and then with
4ml 4% PFA in PBS, followed by overnight fixation in 4% PFA. They were then placed in
gradually increasing sucrose solutions (10%/15%/30%), each overnight, for
cryopreservation, followed by embedding in OCT and sectioning at 20μm thickness. The
same antigen retrieval and staining procedure as the paraffin-embedded sections was used.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. Brain MRI and linkage mapping of pontocerebellar hypoplasia with microcephaly
(a–d) T1-weighted sagittal brain MRI images of a neurologically normal individual (a) and
affected individuals CH3102 (b), CH2402 (c), and CH2701 (d) are shown. Compared to
control, affected individuals show mild reduction in cortical volume, thinning of the corpus
callosum, and severe hypoplasia of the pons, cerebellar vermis, and cerebellar hemispheres.
(e) Family 1 is a consanguineous pedigree from Peru in which three children from two
branches are affected. Family 2 and 3 are both from Puerto Rico. Below each child in
Family 1 and 2 is their Affymetrix 250K Sty SNP data (red and blue = homozygous SNP
call; yellow = heterozygous SNP call), showing a region of homozygosity shared by all
affected individuals in distal chromosome 16q. The graph aligned with the SNP genotyping
data shows multipoint LOD scores calculated from microsatellite maker analysis of Family
1. Genes in the region of LOD > 3 are indicated to the right of the graph.
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tFigure 2. Loss-of-function mutations in CHMP1A, and dysregulation of INK4A in cell lines from
affected individuals
(a) Chromatograms of genomic DNA sequencing show homozygous mutations in intron 2
(CH3101; c.28-13G>A) and in exon 3 (CH2401; c.88C>T). Mutations are highlighted in red
with arrows. (b) A schematic diagram of full length CHMP1A showing the relative
contribution of each exon to the 196 amino acids of the protein. The expected effect of the
mutation in CH2401 is a premature termination of translation after 29 amino acids. The
intronic mutation in CH3101 creates a novel splice acceptor site, and usage of this novel
acceptor causes a frameshift after exon 2, resulting in a termination of translation after 36
amino acids. (c) Western blot analysis of lysates from lymphoblastoid cell lines from
CH2401 and CH3101 demonstrates a complete loss of expression of a 24 kD band detected
by a CHMP1A antibody in control lysate (CTRL). Lysates from a cell line generated from
CH3103 (the mother of CH3101) shows 50% of protein level relative to control. Levels of
protein expression were normalized to the 40 kD beta-actin loading control band. (d)
Lymphoblastoid cell lines from CH2401 and CH3101 proliferate at a much lower rate
compared to control cell lines, tracked over a 4 day period. (e) Quantitative PCR (qPCR) of
cDNA levels from human lymphoblastoid cell lines from CH2401 and CH3101 show a
nearly two-fold increase in expression of INK4A relative to an unrelated, neurologically
normal control cell line (normalized to GAPDH expression levels). The other transcribed
isoform at the locus, ARF, shows no significant difference in expression level between cells
from affected individuals and control. (f) Chromatin immunoprecipitation (ChIP)-qPCR
from lymphoblastoid cell lines using a BMI1 antibody shows an approximate eight-fold
enrichment of INK4A promoter DNA relative to probes targeted 7kb upstream (7kb US) of
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tthe locus in a control cell line. This enrichment is reduced by nearly half in cell lines derived
from CH2401 with a homozygous mutation in CHMP1A. However, enrichment at the ARF
promoter is not significantly different from the control cell line. Error bars in the graphs (d-
f) represent standard error of the mean.
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tFigure 3. Genetic links between CHMP1A and BMI1 in zebrafish and mice
(a, b) Compared to parasagittal section of control zebrafish 5 days post fertilization (a),
zebrafish injected with chmp1a morpholino (MO) show a reduction in cerebellum and
forebrain volume. Higher magnification images of the cerebellum (insets) highlight loss of
molecular and internal granular layers in the mutant (arrowheads). (c-g) Compared to
control zebrafish (c), morpholino-based knockdown of chmp1a (d) shows a reduction in
head size, with the hindbrain more markedly reduced in thickness (asterisks), which is
similar to the phenotype seen by knocking down the zebrafish orthologues of BMI1, bmi1a
and bmi1b (e). When the cdkn2a morpholino is co-injected with the chmp1a morpholino, the
chmp1a knockdown phenotype is partially rescued (f). Embryos are classified at 28 hours
post fertilization as either normal, disrupted, or severely disrupted (see Online Methods) for
each of uninjected controls, cdkn2a MO, bmi1 MO chmp1a MO, bmi1 MO coinjected with
cdkn2a MO, and chmp1a MO coinjected with cdkn2a MO or human CHMP1A mRNA (g).
(h, i) Compared to the wildtype mouse cerebellum at P25 (h), sagittal cross-sectional area of
the Bmi1−/− mouse cerebellum at the same age (i) is dramatically reduced, though foliation
and structure of the lobules (indicated in Roman numerals) are generally preserved. Scale
bars = 200μm (a, b), 200μm (c–f), 500μm (h, i). Asterisk = p < 0.001, two-tailed Pearson’s
chi-squared test (g).
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tFigure 4. Chmp1a and Bmi1 expression in cultured cells and the developing mouse brain
(a) Immunocytochemistry of NIH 3T3 cells shows cytoplasmic Chmp1a staining with
exclusion from the nucleus, where Bmi1 is present. (b) Immunocytochemistry of HEK293T
cells also shows cytoplasmic Chmp1a staining, with some nuclear immunoreactivity. (c) In
dissociated cerebellar granule cells (Cb GC), endogenous Chmp1a localizes mostly to the
cytoplasm, but also has a speckled nuclear localization. (d) When dissociated cerebellar
granule cells are transfected with an HA-tagged Chmp1a overexpression construct (Cb GC
OX), HA-Chmp1a is expressed robustly in the nucleus with prominent nuclear puncta
(arrowheads). (e) In the developing cerebellum at postnatal day 2 (P2 Cb), Chmp1a is
expressed in the nucleus and cytoplasm of cells in the external germinal layer (EGL),
Purkinje cells (PC) and cells in the internal granule layer (IGL). Bmi1 is expressed in these
cells that are positive for Chmp1a, and it primarily localizes to the nucleus. (f) In the nucleus
of P2 EGL cells (P2 EGL), Chmp1a shows speckled staining. The Chmp1a signals are
sometimes seen adjacent to the Bmi1 signals, but they rarely colocalize. (g) In the
developing cerebral cortex at E13.5 (E13.5 Ctx), Chmp1a is expressed in both ventricular
zone progenitors and cortical plate cells. Bmi1 is expressed in the same population of cells.
svz/vz = subventricular and ventricular zones. cp=cortical plate. Scale bars = 20μm (a–e, g),
5μm (f).
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